Cue Biopharma (CUE) Competitors $1.01 -0.01 (-0.98%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CUE vs. CMRX, ATYR, HRTX, MRSN, FULC, ACB, LXEO, FATE, ZNTL, and DMACShould you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Chimerix (CMRX), Atyr PHARMA (ATYR), Heron Therapeutics (HRTX), Mersana Therapeutics (MRSN), Fulcrum Therapeutics (FULC), Aurora Cannabis (ACB), Lexeo Therapeutics (LXEO), Fate Therapeutics (FATE), Zentalis Pharmaceuticals (ZNTL), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Cue Biopharma vs. Chimerix Atyr PHARMA Heron Therapeutics Mersana Therapeutics Fulcrum Therapeutics Aurora Cannabis Lexeo Therapeutics Fate Therapeutics Zentalis Pharmaceuticals DiaMedica Therapeutics Cue Biopharma (NASDAQ:CUE) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, community ranking, earnings, valuation, risk and media sentiment. Which has better earnings and valuation, CUE or CMRX? Cue Biopharma has higher revenue and earnings than Chimerix. Chimerix is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCue Biopharma$9.53M6.71-$50.73M-$0.90-1.12Chimerix$159K1,691.25-$82.10M-$0.94-3.18 Which has more volatility & risk, CUE or CMRX? Cue Biopharma has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Do insiders & institutionals have more ownership in CUE or CMRX? 35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 12.3% of Cue Biopharma shares are owned by insiders. Comparatively, 13.1% of Chimerix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor CUE or CMRX? In the previous week, Chimerix had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 5 mentions for Chimerix and 4 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 1.67 beat Chimerix's score of 0.12 indicating that Cue Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Chimerix 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is CUE or CMRX more profitable? Chimerix has a net margin of 0.00% compared to Cue Biopharma's net margin of -468.02%. Chimerix's return on equity of -50.78% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cue Biopharma-468.02% -156.38% -88.07% Chimerix N/A -50.78%-44.94% Do analysts prefer CUE or CMRX? Cue Biopharma currently has a consensus target price of $5.00, indicating a potential upside of 395.05%. Chimerix has a consensus target price of $8.50, indicating a potential upside of 184.28%. Given Cue Biopharma's higher possible upside, analysts plainly believe Cue Biopharma is more favorable than Chimerix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Chimerix 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer CUE or CMRX? Chimerix received 247 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 63.80% of users gave Chimerix an outperform vote while only 52.33% of users gave Cue Biopharma an outperform vote. CompanyUnderperformOutperformCue BiopharmaOutperform Votes14652.33% Underperform Votes13347.67% ChimerixOutperform Votes39363.80% Underperform Votes22336.20% SummaryChimerix beats Cue Biopharma on 9 of the 17 factors compared between the two stocks. Ad DTICackling Kamala hates this companyDo you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution. Before that happens, you need to see the details here. Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUE vs. The Competition Export to ExcelMetricCue BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.62M$6.57B$5.14B$9.08BDividend YieldN/A2.98%5.09%4.23%P/E Ratio-1.1210.5089.8217.18Price / Sales6.71195.801,116.21116.95Price / CashN/A57.1642.8937.86Price / Book1.235.094.784.78Net Income-$50.73M$151.83M$120.23M$225.60M7 Day Performance7.45%-2.13%-1.92%-1.23%1 Month Performance-1.94%-3.10%11.49%3.36%1 Year Performance-64.18%11.54%30.57%16.60% Cue Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CUECue Biopharma4.687 of 5 stars$1.01-1.0%$5.00+395.0%-63.1%$64.62M$9.53M-1.1260News CoveragePositive NewsCMRXChimerix4.3425 of 5 stars$2.88-2.4%$8.50+195.1%+218.1%$259.03M$320,000.00-3.1472ATYRAtyr PHARMA2.4771 of 5 stars$3.08+0.7%$19.25+525.0%N/A$258.54M$235,000.00-3.2656News CoverageHRTXHeron Therapeutics3.9582 of 5 stars$1.68+4.7%$5.67+238.3%-2.5%$254.76M$137.74M-8.89300Analyst DowngradeMRSNMersana Therapeutics4.3105 of 5 stars$2.06-4.2%$6.00+191.3%-16.2%$254.47M$36.85M-3.52150Positive NewsFULCFulcrum Therapeutics1.7135 of 5 stars$4.44+12.1%$9.33+110.2%-22.6%$239.49M$80.87M-13.68100ACBAurora Cannabis0.0886 of 5 stars$4.29-0.5%N/A-8.4%$235.26M$200.35M-5.671,073Analyst RevisionNews CoverageLXEOLexeo Therapeutics2.7842 of 5 stars$7.01+1.9%$23.80+239.5%-54.8%$231.79M$650,000.00-2.1858News CoverageGap DownFATEFate Therapeutics3.5326 of 5 stars$2.02+10.1%$6.75+235.0%-45.1%$229.50M$13.45M-1.22550ZNTLZentalis Pharmaceuticals1.9987 of 5 stars$3.21+3.9%$10.00+211.5%-77.9%$228.75MN/A-1.24160DMACDiaMedica Therapeutics0.8119 of 5 stars$5.33-0.9%$7.00+31.3%+141.0%$227.91MN/A-9.6120News CoverageGap Down Related Companies and Tools Related Companies Chimerix Alternatives Atyr PHARMA Alternatives Heron Therapeutics Alternatives Mersana Therapeutics Alternatives Fulcrum Therapeutics Alternatives Aurora Cannabis Alternatives Lexeo Therapeutics Alternatives Fate Therapeutics Alternatives Zentalis Pharmaceuticals Alternatives DiaMedica Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CUE) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CUE Stock Alerts